Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
RECK
Introduction
Reversion-inducing-cysteine-rich protein with kazal motifs, also known as RECK, is a human gene,[1] thought to be a metastasis suppressor.
The protein encoded by this gene is a cysteine-rich, extracellular protein with protease inhibitor-like domains whose expression is suppressed strongly in many tumors and cells transformed by various kinds of oncogenes. In normal cells, this membrane-anchored glycoprotein may serve as a negative regulator for matrix metalloproteinase-9, a key enzyme involved in tumor invasion and metastasis.[1] It is one of the targets of an oncomiR, MIRN21.
References
References
Further reading
Further reading
- Takahashi C, Sheng Z, Horan TP, et al. (1998). “Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK”. Proc. Natl. Acad. Sci. U.S.A. 95 (22): 13221–6. doi:10.1073/pnas.95.22.13221. PMC 23764. PMID 9789069.
- Gerstein M (1998). “Measurement of the effectiveness of transitive sequence comparison, through a third ‘intermediate’ sequence”. Bioinformatics. 14 (8): 707–14. doi:10.1093/bioinformatics/14.8.707. PMID 9789096.
- Oh J, Takahashi R, Kondo S, et al. (2002). “The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis”. Cell. 107 (6): 789–800. doi:10.1016/S0092-8674(01)00597-9. PMID 11747814.
- Eisenberg I, Hochner H, Sadeh M, et al. (2003). “Establishment of the genomic structure and identification of thirteen single-nucleotide polymorphisms in the human RECK gene”. Cytogenet. Genome Res. 97 (1–2): 58–61. doi:10.1159/000064042. PMID 12438739.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Masui T, Doi R, Koshiba T, et al. (2004). “RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis”. Clin. Cancer Res. 9 (5): 1779–84. PMID 12738734.
- Liu LT, Chang HC, Chiang LC, Hung WC (2003). “Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion”. Cancer Res. 63 (12): 3069–72. PMID 12810630.
- Ota T, Suzuki Y, Nishikawa T, et al. (2004). “Complete sequencing and characterization of 21,243 full-length human cDNAs”. Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
- Humphray SJ, Oliver K, Hunt AR, et al. (2004). “DNA sequence and analysis of human chromosome 9”. Nature. 429 (6990): 369–74. doi:10.1038/nature02465. PMC 2734081. PMID 15164053.
- Takeuchi T, Hisanaga M, Nagao M, et al. (2005). “The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer”. Clin. Cancer Res. 10 (16): 5572–9. doi:10.1158/1078-0432.CCR-03-0656. PMID 15328199.
- Simizu S, Takagi S, Tamura Y, Osada H (2005). “RECK-mediated suppression of tumor cell invasion is regulated by glycosylation in human tumor cell lines”. Cancer Res. 65 (16): 7455–61. doi:10.1158/0008-5472.CAN-04-4446. PMID 16103099.
- Hsu MC, Chang HC, Hung WC (2006). “HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion”. J. Biol. Chem. 281 (8): 4718–25. doi:10.1074/jbc.M510937200. PMID 16377629.
- Correa TC, Brohem CA, Winnischofer SM, et al. (2006). “Downregulation of the RECK-tumor and metastasis suppressor gene in glioma invasiveness”. J. Cell. Biochem. 99 (1): 156–67. doi:10.1002/jcb.20917. PMID 16791855.
- Chang HC, Cho CY, Hung WC (2007). “Silencing of the metastasis suppressor RECK by RAS oncogene is mediated by DNA methyltransferase 3b-induced promoter methylation”. Cancer Res. 66 (17): 8413–20. doi:10.1158/0008-5472.CAN-06-0685. PMID 16951151.
- Lei H, Hemminki K, Altieri A, et al. (2007). “Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression”. Breast Cancer Res. Treat. 103 (1): 61–9. doi:10.1007/s10549-006-9345-2. PMID 17033924.
- Chang HC, Cho CY, Hung WC (2007). “Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer”. Cancer Sci. 98 (2): 169–73. doi:10.1111/j.1349-7006.2006.00367.x. PMID 17233834.
- Kang HG, Kim HS, Kim KJ, et al. (2007). “RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness”. J. Orthop. Res. 25 (5): 696–702. doi:10.1002/jor.20323. PMID 17262820.
- Mori T, Moriuchi R, Okazaki E, et al. (2007). “Tgat oncoprotein functions as an inhibitor of RECK by association of the unique C-terminal region”. Biochem. Biophys. Res. Commun. 355 (4): 937–43. doi:10.1016/j.bbrc.2007.02.051. PMID 17328864.
- Miki T, Takegami Y, Okawa K, et al. (2007). “The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase N and modulates their endocytic pathways”. J. Biol. Chem. 282 (16): 12341–52. doi:10.1074/jbc.M610948200. PMID 17329256.
- Cho CY, Wang JH, Chang HC, et al. (2007). “Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells”. J. Cell. Physiol. 213 (1): 65–9. doi:10.1002/jcp.21089. PMID 17443689.